What Briumvi treats
Briumvi (ublituximab-xiiy) is a monoclonal antibody medication designed to treat relapsing forms of multiple sclerosis (MS). By specifically targeting and depleting B cells, which are involved in the abnormal immune response in MS, Briumvi helps reduce the frequency of relapses and slows the progression of physical disability, offering significant relief to those living with this chronic neurological condition.
Benefits of Briumvi
Patients using Briumvi often experience significant benefits, such as a reduction in the frequency of relapses, slower progression of physical disability, and an overall improvement in quality of life. Briumvi’s targeted action on B cells offers a focused approach to managing MS, and its infusion schedule allows for consistent and controlled treatment.
Possible Side Effects of Briumvi
While Briumvi is generally well-tolerated, some patients may experience side effects, including infusion-related reactions such as fever, chills, and headache. Other potential side effects include infections, low levels of certain blood cells, and allergic reactions. Serious side effects are rare but can include an increased risk of serious infections and potential liver problems. It’s important to monitor your health closely and report any unusual symptoms to your healthcare provider.
How infusion works at Prime
Briumvi is administered at our infusion centers across New York and Atlanta. Our dedicated care team coordinates every step of your treatment with your prescribing physician.
Getting started
Patients: if you have a referral for Briumvi, send us an inquiry using the form below and our care team will take it from there. Physicians: referring a patient to Prime Infusions is simple — just complete and fax or email the referral form above.
Ready to start?
For a medical emergency, call 911.
Our Infusion Centers
FAQ
Frequently asked questions
How Does Briumvi Work?
Briumvi works by targeting CD20, a protein found on the surface of B cells. These B cells play a key role in the autoimmune process that damages the central nervous system in multiple sclerosis. By binding to CD20, Briumvi selectively depletes these B cells, reducing their ability to contribute to the inflammatory process that leads to MS relapses and progression. Briumvi is administered through intravenous infusion, with dosing tailored to the patient’s specific condition and response to treatment.
Who is Briumvi For?
Briumvi is suitable for adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. It is often prescribed for patients who have not responded adequately to other disease-modifying therapies or who require a more targeted approach to managing their MS.